Camilla Nystrand Länsman

Camilla Nystrand Länsman

Adjunct Lecturer
Visiting address: Tomtebogatan 18a, 17165 Solna
Postal address: C7 Lärande, Informatik, Management och Etik, C7 Hälsoekonomi och Policy Rehnberg Heintz, 171 77 Stockholm
Part of:

About me

  • I work as a health economist at the Stockholm Centre for Health Economics
    (StoCHE) at the Centre for Health Economics, Informatics and Health Care
    Research (CHIS) at Stockholm Region. I am also affiliated to research at LIME
    at KI.
    At StoCHE, I work mainly with health economic evaluations of different
    interventions that Stockholm Region needs to make decisions about.
    I have previously worked as a health economist at the National Board of
    Health and Welfare and have a PhD in health economics from Uppsala
    University.
    I have a Master's degree in development economics from the University of
    Amsterdam and defended my thesis in health economics in 2021, at the Faculty
    of Medicine at Uppsala University. My dissertation examined the value of
    social investments, with a focus on parenting programs. Furthermore, I worked
    extensively on developing calculation tools for municipalities that can be
    used to forecast the value of preventive interventions.

Research

  • My research focuses on examining the economic value of different types of
    interventions in health care and other sectors where interventions can have
    an impact on health. I work broadly on issues ranging from primary prevention
    to treatment. What drives me forward in research is the ability to produce
    information that may be valouable for decision makers, and that contributes
    to the best possible health, for all, based on the limited resources we have
    in society.

Articles

All other publications

Grants

  • Swedish Research Council
    1 January 2025 - 31 December 2027
    Colorectal cancer (CRC) is the third most common cancer worldwide and the most resource consuming and costly cancer. Primary and secondary prevention of CRC with screening can reduce deaths from the disease by removal of polyps and detection of cancer at an early curable stage. In a quasi-randomized study design, the Swedish region of Stockholm-Gotland started population-based screening in 2008. 400,000 individuals were invited or not to biennial fecal occult blood testing and were referred to colonoscopy when tested positive. After 14 years of follow-up, the CRC mortality was reduced 14% with invitation to screening. In 2026, 1,65 million people will be included in the program.The overall aim of the project is to build a CRC risk-prediction model to be used in screening practice to individualize continued screening within the program or adenoma surveillance. Together with the outcomes of screening, we will provide potential predictors to the model by analyzing associations of the colon microbiota and the exposure to modifiable and unmodifiable risk factors and CRC development. We will also evaluate the cost-effectiveness of screening regarding healthcare consumption, but also the indirect costs in a societal perspective, and biobank mucosa biopsies and blood samples for future research. Our results will provide evidence to reduce unnecessary screening follow-up while cost-effectively preserve the benefit of CRC risk- and mortality reduction with population-based screening.
  • Swedish Research Council
    1 January 2024 - 31 January 2026

News from KI

Events from KI